Caisse Des Depots ET Consignations Cuts Stock Holdings in Gilead Sciences, Inc. $GILD

Caisse Des Depots ET Consignations lowered its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 17.0% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 61,056 shares of the biopharmaceutical company’s stock after selling 12,496 shares during the quarter. Caisse Des Depots ET Consignations’ holdings in Gilead Sciences were worth $6,777,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. GoalVest Advisory LLC lifted its holdings in Gilead Sciences by 7,566.7% during the second quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 227 shares during the period. Corundum Trust Company INC bought a new position in shares of Gilead Sciences in the 3rd quarter worth $26,000. Harbor Asset Planning Inc. bought a new position in shares of Gilead Sciences in the 2nd quarter worth $27,000. Putney Financial Group LLC lifted its stake in shares of Gilead Sciences by 53.4% during the 2nd quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 94 shares during the last quarter. Finally, Howard Hughes Medical Institute bought a new stake in Gilead Sciences during the second quarter valued at about $30,000. 83.67% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CEO Daniel Patrick O’day sold 115,640 shares of Gilead Sciences stock in a transaction that occurred on Friday, January 23rd. The shares were sold at an average price of $135.00, for a total transaction of $15,611,400.00. Following the completion of the sale, the chief executive officer directly owned 566,698 shares in the company, valued at approximately $76,504,230. The trade was a 16.95% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Johanna Mercier sold 28,000 shares of the stock in a transaction on Monday, November 17th. The stock was sold at an average price of $125.86, for a total transaction of $3,524,080.00. Following the completion of the sale, the insider owned 107,193 shares in the company, valued at $13,491,310.98. The trade was a 20.71% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 319,391 shares of company stock valued at $44,141,101. 0.27% of the stock is owned by corporate insiders.

Gilead Sciences Price Performance

NASDAQ GILD opened at $155.80 on Thursday. The company has a market cap of $193.30 billion, a price-to-earnings ratio of 23.01, a PEG ratio of 0.78 and a beta of 0.36. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.45 and a quick ratio of 1.31. The stock’s fifty day moving average price is $129.01 and its 200 day moving average price is $121.77. Gilead Sciences, Inc. has a 1 year low of $93.37 and a 1 year high of $157.29.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share for the quarter, beating the consensus estimate of $1.83 by $0.03. The business had revenue of $7.93 billion for the quarter, compared to the consensus estimate of $7.68 billion. Gilead Sciences had a return on equity of 51.04% and a net margin of 28.90%.The company’s quarterly revenue was up 4.7% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.90 EPS. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. As a group, equities research analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, March 30th. Investors of record on Friday, March 13th will be issued a $0.82 dividend. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.79. The ex-dividend date is Friday, March 13th. This represents a $3.28 annualized dividend and a yield of 2.1%. Gilead Sciences’s dividend payout ratio is currently 46.68%.

Wall Street Analyst Weigh In

A number of equities analysts have commented on GILD shares. Citigroup boosted their target price on shares of Gilead Sciences from $140.00 to $156.00 and gave the stock a “buy” rating in a report on Tuesday, January 27th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Gilead Sciences in a research report on Thursday, January 22nd. TD Cowen increased their target price on shares of Gilead Sciences from $125.00 to $145.00 and gave the company a “buy” rating in a research report on Thursday, January 29th. UBS Group raised their target price on shares of Gilead Sciences from $145.00 to $155.00 and gave the company a “buy” rating in a research note on Monday, January 26th. Finally, Wall Street Zen downgraded Gilead Sciences from a “strong-buy” rating to a “buy” rating in a research report on Friday, January 23rd. Twenty-four research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $146.44.

More Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Q4 beat — Gilead reported Q4 EPS and revenue above Street estimates, driven by strong HIV and liver‑disease franchise performance; investors see the quarter as confirmation of core portfolio strength. Reuters: Gilead quarterly results beat Wall Street estimates
• Positive Sentiment: Analysts raise forecasts and price targets — Multiple firms (Morgan Stanley, JPMorgan, Wells Fargo, Needham, Scotiabank, Cantor Fitzgerald, etc.) lifted price targets and reiterated Buy/Overweight calls after the quarter, supporting further upside. MarketScreener: Morgan Stanley PT raise (example)
• Positive Sentiment: Dividend raise — Board increased the quarterly dividend to $0.82 (3.8% bump), boosting yield and appealing to income-oriented holders. BusinessWire: Dividend announcement
• Positive Sentiment: Product & label catalysts — Coverage notes (and analyst commentary) highlight Yeztugo’s market debut and potential CAR‑T (Yescarta) label expansions as multi‑year growth drivers. Yahoo Finance: Yescarta label expansion and dividend growth
• Neutral Sentiment: Street reactions and notes — Several analyst notes and earnings transcripts highlight margin expansion and HIV momentum; views vary on how much upside is baked into current multiples. Seeking Alpha: Q4 earnings call transcript
• Neutral Sentiment: Odd short‑interest data — Recent feeds show anomalous/zero short interest figures (likely a reporting artifact); currently not a clear market pressure signal. (internal short interest entries)
• Negative Sentiment: Light FY‑2026 guidance — Management set FY‑2026 EPS and revenue guidance slightly below consensus, which initially prompted an after‑hours pullback and keeps some investors cautious about near‑term upside. MSN: Guidance seen as light
• Negative Sentiment: Some conservative analyst calls — A few firms (example: RBC) set price targets that imply downside versus current levels, reflecting caution around the guidance and near‑term execution risk. Benzinga: RBC PT update (example)

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.